It was shown that DEFA1 displays a broad spectrum of antimicrobial activity against both fermenting and non-fermenting Gram-negative strains, against Gram-positive cocci, spore-forming bacilli, and the yeast Candida (C.) albicans
Clinical investigation to support new uses generally requires an Investigational New Drug (IND) application with appropriate chemistry, manufacturing, and controls, nonclinical safety, and human data
Why Are Researchers Interested in Both Compounds
This method is ideal for researchers who prefer non-invasive and hassle-free administration
Voltage-gated ion channels that open or close in response to changes in the membrane potential
This is an important consideration when evaluating BPC-157s therapeutic potential